Structure reports early oral amylin-drug results, with gastrointestinal tolerability questions

Structure Therapeutics reported initial human findings for its experimental oral drug ACCG-2671 on September 8, advancing another approach to obesity treatment while exposing a central development question: whether repeated treatment can produce useful weight reduction with acceptable gastrointestinal effects. The company has begun a longer study in participants with obesity.

The disclosure concerns an early safety and pharmacology experiment, rather than an established obesity treatment. ACCG-2671 is a non-peptide small molecule that activates amylin and calcitonin receptors. Its relevance to peptide therapeutics comes from the hormonal pathways it targets, although the drug itself is chemically distinct from a peptide.

### What the first human study measured

The single-dose portion of the Phase 1/2a program enrolled 31 healthy adults without obesity. According to the company’s presentation furnished to the Securities and Exchange Commission, participants were randomized in a three-to-one allocation to active treatment or placebo across ascending-dose groups.

The primary objectives were safety, tolerability and pharmacokinetics—how the compound moves through and persists in the body. Changes in weight and bone-related blood markers were exploratory measurements. Eligibility covered adults aged 25 to 65, limiting what this experiment can establish about older or medically complex populations.

Structure reported a terminal half-life of approximately six days. That finding supports investigating different treatment frequencies, but does not establish an effective or safe long-term schedule. Drug persistence is one input into development; repeated exposure still requires direct testing.

The six participants in the highest-dose group had a mean weight reduction of 3.3% at day 24. This was a change from baseline, not a reported placebo-adjusted treatment effect. Such a small, short observation cannot establish sustained weight management, effects on body composition or improvements in healthspan.

### Tolerability deserves equal attention

The sponsor reported no serious adverse events, drug-related treatment discontinuations or drug-induced liver injury in the single-dose study. Those observations are reassuring within the narrow experiment, but the sample was too small and follow-up too brief to rule out uncommon or delayed harms.

Gastrointestinal symptoms increased in the higher-dose groups. The accompanying safety table reported nausea and vomiting in all six participants receiving the highest dose, with those events classified as mild or moderate. Both symptoms also occurred in the next-highest group.

This makes tolerability a substantive part of the result. The weight signal and gastrointestinal findings need to be considered together when assessing whether the compound warrants larger trials. The current evidence cannot determine how those symptoms affected the observed weight changes or predict whether tolerability will improve during repeated treatment.

### What comes next

The company says the randomized, placebo-controlled multiple-dose portion will examine treatment over 84 days in participants with obesity. It will assess safety, tolerability and drug exposure across five cohorts, including an exploratory cohort receiving an established injectable GLP-1 receptor agonist. Results are expected in the first half of 2027; that remains a sponsor projection.

For clinicians and researchers following metabolic drug development, the immediate significance is evidence that the oral compound reaches sustained exposure in humans and warrants further investigation. The next study must clarify whether its biological activity translates into a usable benefit-risk profile.

The September findings were disclosed through company materials and an SEC filing, rather than a peer-reviewed clinical report. They do not establish superiority over other obesity medicines, protection against cardiovascular disease or an extension of healthy life. ACCG-2671 remains investigational.